SCHEMBL33532844

SCHEMBL33532844

CC1c2cccc(N3CCNCC3)c2CCN1C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UCHL1 P09936 5/20 0.44
HTR6 P50406 3/20 0.39
GPR119 Q8TDV5 1/20 0.38
F11 P03951 2/20 0.37
NOTUM Q6P988 1/20 0.37
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
ADRB1 P08588 2/20 0.36
NR1H2 P55055 1/20 0.36
DRD2 P14416 2/20 0.36
DRD3 P35462 2/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
SIGMAR1 Q99720 1/20 0.36
HTR1A P08908 1/20 0.36
DRD4 P21917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24495434 0.81 UCHL1 (0.43) UCHL1DDB1CRBNNR1H2DRD2
SCHEMBL30682966 0.81 UCHL1 (0.43) UCHL1DDB1CRBNNR1H2DRD2
SCHEMBL30878641 0.81 GPR119 (0.45) UCHL1GPR119DDB1CRBNHTR2C
SCHEMBL29607370 0.80 UCHL1 (0.55) UCHL1GPR119DDB1CRBNNR1H2
SCHEMBL29608082 0.80 UCHL1 (0.55) UCHL1GPR119DDB1CRBNNR1H2
SCHEMBL29607737 0.80 UCHL1 (0.55) UCHL1GPR119DDB1CRBNNR1H2
SCHEMBL17681690 0.80 UCHL1 (0.55) UCHL1GPR119DDB1CRBNNR1H2
SCHEMBL17681742 0.80 UCHL1 (0.55) UCHL1GPR119DDB1CRBNNR1H2
SCHEMBL7996670 0.80 UCHL1 (0.43) UCHL1GPR119DDB1CRBNNR1H2
SCHEMBL17681740 0.80 UCHL1 (0.55) UCHL1GPR119DDB1CRBNNR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LTD (GB) 2026-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION BCL9L, RBBP9, BRD9 UCHL1 261/4885HTR6 1932/4885GPR119 3701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.